TREATMENT WITH OXANDROLONE AND THE DURABILITY OF EFFECTS IN OLDER MEN

氧雄龙治疗及其对老年男性疗效的持久性

• 批准号: 7355250
• 负责人: E TODD SCHROEDER
• 金额: $ 0.59万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-02-01 至 2007-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7355250
• 关键词: TREATMENT; OXANDROLONE; DURABILITY; EFFECTS; OLDER

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We investigated the effects of the anabolic androgen, oxandrolone, on lean body mass (LBM), muscle size, fat, and maximum voluntary muscle strength, and we determined the durability of effects after treatment was stopped. Thirty-two healthy 60- to 87-yr-old men were randomized to receive 20 mg oxandrolone/day (n = 20) or placebo (n = 12) for 12 wk. Body composition [dual-energy X-ray absorptiometry (DEXA), magnetic resonance imaging, and 2H2O dilution] and muscle strength [1 repetition maximum (1 RM)] were evaluated at baseline and after 12 wk of treatment; body composition (DEXA) and 1-RM strength were then assessed 12 wk after treatment was discontinued (week 24). At week 12, oxandrolone increased LBM by 3.0 ¿ 1.5 kg (P < 0.001), total body water by 2.9 ¿ 3.7 kg (P = 0.002), and proximal thigh muscle area by 12.4 ¿ 8.4 cm2 (P < 0.001); these increases were greater (P < 0.003) than in the placebo group. Oxandrolone increased 1-RM strength for leg press by 6.7 ¿ 6.4% (P < 0.001), leg flexion by 7.0 ¿ 7.8% (P < 0.001), chest press by 9.3 ¿ 6.7% (P < 0.001), and latissimus pull-down exercises by 5.1 ¿ 9.1% (P = 0.02); these increases were greater than placebo. Oxandrolone reduced total (-1.9 ¿ 1.0 kg) and trunk fat (-1.3 ¿ 0.6 kg; P < 0.001), and these decreases were greater (P < 0.001) than placebo. Twelve weeks after oxandrolone was discontinued (week 24), the increments in LBM and muscle strength were no longer different from baseline (P > 0.15). However, the decreases in total and trunk fat were sustained (-1.5 ¿ 1.8, P = 0.001 and -1.0 ¿ 1.1 kg, P < 0.001, respectively). Thus oxandrolone induced short-term improvements in LBM, muscle area, and strength, while reducing whole body and trunk adiposity. Anabolic improvements were lost 12 wk after discontinuing oxandrolone, whereas improvements in fat mass were largely sustained.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。我们研究了合成代谢雄激素奥雄酮对瘦体重(LBM)、肌肉大小、脂肪和最大自主肌力的影响，并确定了治疗停止后影响的持久性。32名60岁至87岁的健康男性被随机分成两组，每天服用20毫克的奥昔洛酮(n=20)或服用安慰剂(n=12)，疗程12周。在基线和治疗12wk后评估身体成分[双能X射线吸收测量仪(DEXA)、磁共振成像和2H2O稀释]和肌力[1重复最大值(1rm)]；然后在停止治疗12wk(24周)后评估体成分(DEXA)和1-rm力量。在12周时，奥昔多龙使体重增加了3.00±1.5公斤(P&lt；0.001)，全身水分增加了2.90±3.7公斤(P=0.002)，大腿近端肌肉面积增加了12.4士8.4cm2(P&lt；0.001)，这些增加幅度比安慰剂组更大(P&lt；0.003)。与安慰剂组相比，氧可酮增加了1-rM力量6.7%±6.4%(P&lt；0.001)、7.0%±7.8%(P&lt；0.001)、9.3%±6.7%(P&lt；0.001)和5.1%±9.1%(P=0.02)。奥曲酮减少了总脂肪(-1.9P&lt；0.001)和躯干脂肪(-1.3x±0.6 kg；P&lt；0.001)，比安慰剂更大。停药12周后(24周)，LBM和肌力的增量与基线无明显差异(P&gt；0.15)。然而，总脂肪和躯干脂肪的下降是持续的(分别为-1.5%±1.8%，P=0.001和-1.0%±1.1 kg，P=0.001)。因此，氧雄酮可以在短期内改善LBM、肌肉面积和力量，同时减少全身和躯干的肥胖。停药12周后，合成代谢的改善消失，而脂肪质量的改善在很大程度上是持续的。